© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
December 24, 2020
Dolly Sharma, PhD , Jeffrey Wojtynek, PharmD , Kathleen M. Fox, PhD , Chelsea Cooper, PharmD , Igoni Dokubo, MD
Evidence-Based Oncology, February 2021, Volume 27, Issue 2
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.